 |
|
 |
Hungary |
|
|
The Pharmaceutical Market: Hungary
Publication Date February 2007
Publisher Espicom
Product Type Strategic Report
Pages 86
ISBN Number not applicable
Product Code ESP882
|
|
|
Summary
Espicom's in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.
In May 2004, Hungary became a member of the European Union and national legislation has been harmonised with EU Directives. Hungary represents one of the more advanced pharmaceutical markets of Central Europe. The country has a strong tradition of pharmaceutical manufacturing and has always maintained a relatively high level of consumption. However, increased use of expensive drugs, among other factors, has led to an ever-expanding drugs budget deficit. Over the past few years, the government has implemented a number of measures to reduce the deficit, but they have mainly been at the expense of pharmaceutical companies. Recent legislation designed to limit the overspending of the drugs budget has hit the pharmaceutical industry hard. The sector has witnessed a number of changes, particularly since January 2007, including reduced reimbursement rates, new prescription charges and further mandatory contributions from manufacturers. The most recent legislation is likely to result in manufacturers contributing at least twice as much as they did in 2006 towards the drugs bill.
Pharmaceutical production in Hungary is specialised in the production of generic drugs. Generic prescribing will increase in 2007 due to increased pressure on physicians to prescribe the cheapest available drugs. Privatisation of the main pharmaceutical companies took place in the period 1991-1996, starting with Chinoin. Gedeon Richter is controlled by foreign investors, whereas the majority share of equities in other companies are owned by foreign professional investors.
|
Content
BACKGROUND DATA
-
- Chichester, West Sussex, PO20 2FS, United Kingdom
- Geography
- Political Overview
- Economic Overview
- Economic Indicators, 1995-2012
- Population
- Population, 1995-2006
- Population by County, 2002-2006
- Population by Age Group, 2001-2006 (%)
- Population by Age Group and Region, 2006 (%)
- Demographic Indicators
- Principal Demographic Indicators, 1997-2005
- Mortality
- Causes of Death, 2004-2005
- Infant Mortality
- Causes of Infant Mortality, 2004-2005
- Morbidity
- Reported Infectious Diseases, 1999-2006
- Tuberculosis
- HIV/AIDS
- HIV/AIDS Cases, 1990-2005
- Charts
- Map of Hungary
- Population, 1990-2006
- Population by Age Group, 2006 (%)
- Birth, Death and Infant Mortality Rates, 1996-2005
- Causes of Death, 2005 (%)
- Hungary
HEALTHCARE SYSTEM
-
- Chichester, West Sussex, PO20 2FS, United Kingdom
- Organisation & Administration
- Health Expenditure
- Health Insurance Fund
- Health Insurance Fund Expenditure, 2002-2004 (HUF million)
- Health Insurance Financing of Curative Care, 2001-2004 (HUF million)
- Hospital Services
- Hospital Resources
- Hospital Beds by Owner, 1998-2004
- Hospital Beds by Specialty, 2000-2004
- Hospital Activity
- Inpatient Discharges by Specialty, 2000-2004
- Inpatient Discharges by Specialty, 2004
- Patient Days, 2004
- Ambulatory Care
- Outpatient Treatments (000s), 1999-2004
- Family Doctor Service Consultations, 1998-2004 (000s)
- Family Paediatrician Service
- Dental Care
- Dental Services, 1998-2004
- Medical Personnel
- Active Physicians by Specialty, 2002-2004
- Other Medical Personnel, 2002-2004
- Charts
- Private Healthcare Provision by Category, 2001 (%)
- Hospital USAge by Age Group, 2003 (%)
- Hospital Beds by Owner, 2004 (%)
- Patient Days by Specialty, 2004 (%)
- Hungary
ACCESSING THE PHARMACEUTICAL MARKET
-
- Chichester, West Sussex, PO20 2FS, United Kingdom
- Introduction
- Regulatory Environment
- EU Regulatory Reforms
- Centralised procedure
- Mutual recognition procedure
- Pharmaceutical Registration
- Marketing Authorisation Fees, 2007
- Advertising
- Patent Protection & Intellectual Property Rights
- Pricing and Reimbursement
- Distribution Channels
- Distributors
- Hungaropharma
- Medimpex
- Pharmafontana
- Pharmacies
- Pharmacies, 1996-2004
- Trade Fairs
- Domestic Production
- Hungarian Pharmaceutical Production, 1990-2005 (HUF billions)
- Trade Associations
- AIPM
- Magyosz
- Domestic Producers
- Biogal
- Chinoin
- Egis
- Egis ANDA Approvals, 2002-2005
- Human Pharmaceuticals by Therapeutic Area, 2001-2005 (HUF millions)
- Egis Financial Results, 2002-2005 (HUF millions)
- Product Sales by Key Market, 2002-2005 (HUF millions)
- Gedeon Richter
- Recent Product Launches
- Gedeon Richter New Product Launches, 2004
- Gedeon Richter Financial Results, 1999-2005 (HUF millions)
- Hungary Accessing The Pharmaceutical Market
- Gedeon Richter Sales by Region, 2003-2005 (HUF millions)
- Products by Therapeutic Group, 2002-2005 (%)
- Human
- ICN Magyarorszag (Alkaloida)
- Keri Pharma
- Pharmavit
- Research & Development
- Directory
- Healthcare Organisations
- Trade Associations
- Charts
- Gedeon Richter Products by Therapeutic Groups, 2005 (%)
- Gedeon Richter Key Markets Breakdown, 2005 (%)
|
|
|
